|
|
|
Oxford Global, Novotel London West, 1 Shortlands, Hammersmith International Ctre, Hammersmith, W6 8DR, London, UK
27 - 29 April 2020
Over 40 case studies, presentations and panel discussions focused on the key issues in peptide technologies, therapeutics case studies, discovery & development of oligonucleotide therapeutics, manufacturing and process development. View Agenda: https://bit.ly/2PP4A5V 27 April 2019 – Day One (Kick-off Session) - Turning Challenges to Successes in Peptides Delivery & Formulation
28 April 2020 – Day Two - Peptide Design, Synthesis, Purification & Analytical Technologies
- Peptide Manufacturing & Process Development
- Oligonucleotide Synthesis, Chemistry, Formulation & Delivery, Process & Analytical Development
29 April 2020 – Day Three - Peptide Therapeutics: Case Studies, Immunogenicity & Novel Disease Treatments
- Oligonucleotide Therapeutics & Manufacturing
2020 Live Webinar Targeted, Controlled and Responsive Therapeutic Delivery through the Design of Self-Assembling Peptide Hydrogels Presented by Aline Miller, Professor, University of Manchester Register: https://bit.ly/2pzwpV9
- Design rules for engineering responsive peptide hydrogels
- Targeting endometriosis with sprayable peptide hydrogels
- Delivery of therapeutics to solid tumours
- Mucoadhesive hydrogels to prolong therapeutic efficacy
|
|
|
|
|
|
Organized by:
|
|
Oxford Global |
|
Invited Speakers:
|
|
- Gene Liau, Executive Vice President and Head, Research & Preclinical Development, Stoke Therapeutics
- Ekkehard Leberer, Senior Director, Sanofi
- Matthew Catley, Research Director, MiNA Therapeutics
- Jennifer Franklin, Director, CMC Regulatory Affairs, IONIS Pharmaceuticals
- Michael Agrez, Chief Executive Officer, InterK Peptide Therapeutics
- David Earp, President and Chief Executive Officer, Circle Pharma
- Ali Tavassoli, Founder and Chief Scientific Officer, Curve Therapeutics
- Olivier Kitten, Founder and Chief Executive Officer, Affilogic
- Alex Batchelor, Chief Executive Officer, Orbit Discovery
- Els Beirnaert, Chief Executive Officer, Aelin Therapeutics
- Andrew Young, Chief Scientific Officer, Intarcia Therapeutics
- & many more
|
|
|
|
|
|
Deadline for Abstracts:
|
|
N/A
|
|
|
|
|
|
Registration:
|
|
https://bit.ly/369yLKG
|
|
|
|
|
|
|
|